Skip to content
2000
Volume 5, Issue 1
  • ISSN: 1566-5232
  • E-ISSN: 1875-5631

Abstract

Cancer gene therapy is the most promising and active field in gene therapy treatment. Although previous experimental and clinical trials have brought forward some exciting cases, in general, the clinical benefits have been limited. A major difference between virus-mediated gene therapy and other therapies is the poor physical diffusibility of viral vectors, which is also one of the major obstacles in cancer gene therapy. As safety is a prerequisite to enhanced viral dissemination, tumor-specific targeting becomes crucial. The present review focuses on questions related to efficient viral dissemination in tumor masses and how to sustain a high level of oncolytic virus targeting of tumor cells only. We will first consider two common reasons for limited virus spread in tumor masses and then discuss strategies for improving the tumor-specific oncolysis of currently used viral vectors and to comment on their advantages and potential problems.

Loading

Article metrics loading...

/content/journals/cgt/10.2174/1566523052997460
2005-02-01
2025-09-28
Loading full text...

Full text loading...

/content/journals/cgt/10.2174/1566523052997460
Loading

  • Article Type:
    Review Article
Keyword(s): Cancer gene therapy; oncolytic virus; tumor masses
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test